Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
866 studies found for:    amyloid
Show Display Options
Rank Status Study
1 Completed Radioimmunoimaging of Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
2 Active, not recruiting Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
Conditions: Amyloidosis;   Paraproteinemias;   Cardiomyopathies
Interventions: Other: Amyloidosis;   Other: Cardiac Amyloidosis
3 Recruiting Escitalopram Effects on CSF Amyloid Beta
Condition: Amyloid Beta Protein
Intervention: Drug: Escitalopram or Placebo
4 Withdrawn F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)
Condition: Cerebral Amyloid Angiopathy
Intervention:
5 Recruiting Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
Conditions: Amyloidosis;   Cardiomyopathy;   Transthyretin Amyloidosis;   Senile Systemic Amyloidosis;   Carpal Tunnel Syndrome
Intervention:
6 Recruiting Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis
Condition: Spontaneous Bacterial Peritonitis
Intervention: Other: serum amyloid A level
7 Completed Serum Amyloid A Protein And Fetuin A Levels
Condition: Periodontal Diseases
Interventions: Biological: Fetuin-A;   Biological: Serum Amyloid A
8 Recruiting Implications for Management of PET Amyloid Classification Technology
Conditions: Mild Cognitive Impairment;   Dementia;   Alzheimer's Disease
Intervention: Drug: [18F]Flutemetamol
9 Active, not recruiting Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy
Conditions: FAP;   Familial Amyloid Polyneuropathy;   TTR;   Transthyretin;   Amyloidosis
Interventions: Drug: IONIS-TTR Rx;   Drug: Placebo
10 Enrolling by invitation Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Conditions: FAP;   Familial Amyloid Polyneuropathy;   TTR;   Transthyretin;   Amyloidosis
Intervention: Drug: IONIS-TTR Rx
11 Recruiting Amyloïd Load in Elderly Population: Effect of Cognitive Reserve
Conditions: Plaque, Amyloid;   Cognitive Deficits
Interventions: Other: PET;   Other: MRI;   Other: neuropsychological tests
12 Completed The Effect of Diflunisal on Familial Amyloidosis
Conditions: Familial Amyloid Polyneuropathy;   Familial Amyloidosis
Interventions: Drug: diflunisal;   Other: placebo
13 Active, not recruiting Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy
Conditions: Intracerebral Hemorrhage;   Cerebral Amyloid Angiopathy;   Ischemic Stroke
Intervention:
14 Enrolling by invitation CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention:
15 Completed Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
16 Completed
Has Results
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Conditions: Down Syndrome;   Amyloid Beta-protein
Intervention: Drug: Florbetaben (BAY94-9172)
17 Not yet recruiting Prevalence of Amyloidosis and Carpal Tunnel
Condition: Amyloid Neuropathy, Carpal Tunnel
Intervention:
18 Recruiting Molecular Imaging of Primary Amyloid Cardiomyopathy
Conditions: Amyloidosis, Primary;   Cardiomyopathy
Interventions: Radiation: F-18 florbetapir/C-11 acetate PET;   Device: MRI
19 Completed How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints
Conditions: Alzheimer's Disease;   Mild Cognitive Impairment
Intervention: Device: Beta amyloid imaging
20 Completed
Has Results
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Condition: Parkinson's Disease
Intervention: Drug: florbetapir F 18

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years